Morphological Changes in Bromocriptine-Treated Pituitary Tumours

References

• Anniko M., Wersäll J. Human pituitary tumours in organ culture with correlation to clinical data. Acta Otolaryngol (Stockh) 1980; 89: 249
   PubMed Web of Science ®Google Scholar
• Anniko M., Holm L. E., Silfverswärd C., Tribukait B., Werner S., Wersäll J. DNA measurements of human pituitary tumours. Acta Otolaryngol (Stockh) 1981; 379: 1, Suppl
   Google Scholar
• Anniko M., Werner S., Wersäll J. Bromocrip-tine induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas. Acta Otolaryngol (Stockh) 1981; 92: 343
   PubMed Web of Science ®Google Scholar
• Anniko M., Wersäll J. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas. Acta Path Microbiol Scand, Sect. A 1981; 89: 41
   Google Scholar
• Bergh T., Bergström K., Larsson S. G., Lundberg P. O., Nillius S. J., Wide L. Bromocriptine-induced tumour regression in two women with prolactin secreting pituitary tumours. Acta Endocrinol (Kbh) 1979; 91: 180
   Google Scholar
• Corenblum B. Bromocriptine in pituitary tumour. Lancet 1978; ii: 786
   Google Scholar
• Cushing H. Surgical experiences with pituitary disorders. JAMA 1914; 63: 1515
   Google Scholar
• Davies C., Jacobi J., Lloyd H. M., Meares J. D. DNA synthesis and the secretion of prolactin and growth hormone by pituitary gland of the male rat: effects of diethylstilboestrol and 2-Br-α-ergocryptine methane-sulphate. J Endocrinol 1974; 61: 411
   PubMedGoogle Scholar
• Del Pozo E., Varga L., Nyss H., Tolis G., Friesen H., Wenner R., Vetter L., Uuthwiter A. Clinical and hormonal response to bromocriptine (CB-154) in the galactorrhea syndromes. J Clin Endocr Metab 1974; 39: 18
   PubMed Web of Science ®Google Scholar
• Fossati P., Strauch G., Tourniaire J. Etude de l'activité de la bromocriptine dans les états d'hyper-prolactinémie. Nouv Presse méd 1976; 5: 1687
   PubMedGoogle Scholar
• Fuxe K., Fredholm B. B., Ögren S. O., Agnati L. F., Hökfelt T., Gustafsson J. Å. Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine. Acta Endocrinol (Kbh) 1978; 216: 27, Suppl
   Google Scholar
• Galvan G., Frick J., Irnberger T. Bromocriptin-induzierte zystische Tumorregression bei fortgeschrit-tenen Prolactinomen. Dtsch med Wschr 1981; 106: 637
   PubMedGoogle Scholar
• Guiot G. Transsphenoidal approach in surgical treatment of pituitary adenomas: general principles and indications in non-functioning adenomas. Int Congr Ser No. 303, Excerpta Medica, Amsterdam 1973; 158
   Google Scholar
• Halstead A. E. Remarks on the operative therapy of tumours of the hypophysis. Surg Gynecol Obstetr 1910; 10: 494
   Google Scholar
• Hamberger C. A. Transantro-sphenoidal hypophys-ectomy. Int Rhinol 1964; 1: 1
   Google Scholar
• Hamberger C. A., Hammer G., Norlén G., Sjögren B. Hypophysectomy in acromegaly. J Clin Endocrinol Metab 1959; 19: 1500
   PubMed Web of Science ®Google Scholar
• Hancock K. N., Scott J. S., Lamb J. T., Gibson R. M., Chapman C. Conservative management of pituitary prolactinomas; evidence for bromocriptine-induced regression. Br J Obstet Gynaecol 1980; 87: 523
   PubMedGoogle Scholar
• Hardy J. Transsphenoidal surgery of the hypersecreting tumours. Diagnosis and Treatment of Pituitary Tumours, R. O. Kohler, G. T. Ross. Int Congr Ser, Excerpta Medica, Amsterdam 1973; 179
   Google Scholar
• Hirsch O. Zur endonasalen Operation von Hypo-physentumoren. Wien Med Wochenschr 1909; 20: 621
   Google Scholar
• Holmgren G. Über einen Fall von Hypophysentumor, erfolgreich nach Hirsch operiert. Z Ohrenheilkd 1912; 66: 39
   Google Scholar
• Kleinberg D. L., Noel G. L., Frantz A. G. Galactorrhea: A study of 235 cases, including 48 pituitary tumours. New Engl J Med 1977; 296: 589
   PubMed Web of Science ®Google Scholar
• Landolt A. M. Ultrastructure of human sella tumours. Acta Neurochir 1975; 22: 1, Suppl
   PubMedGoogle Scholar
• Landolt A. M., Wüthrich R., Fellman H. Regression of pituitary prolactinoma after treatment with bromocriptine. Lancet 1979; i: 1082
   Google Scholar
• Liuzzi A., Chiodini P. G., Botalla L., Cremascoli G., Müller E. E., Silverstroni F. Decreased plasma growth hormone (GH) levels in acromegalies following CB 154 (2-Br-α-ergocryptine) administration. J Clin Endocrinol Metab 1974; 38: 910
   PubMed Web of Science ®Google Scholar
• Lloyd H. M., Meares J. D., Jacobi J. Effects of oestrogens and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975; 255: 497
   PubMedGoogle Scholar
• McGregor A. M., Scanlon M. F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br Med J 1979; ii: 700
   Google Scholar
• McGregor A. M., Scanlon M. F., Hall K., Cooke D. B., Hall R. Reduction in size of a pituitary tumour by bromocriptine therapy. New Engl J Med 1979; 300: 291
   PubMed Web of Science ®Google Scholar
• McLeod R. M., Lehmeyer J. E. Regulation of the synthesis and release of prolactin. Lactogenic Hormones, G. E.W. Wolstenholme, J. Knight. Churchill-Livingstone, London and Edinburgh 1972; 53–74
   Google Scholar
• Saki I. S., Istfan N. Bromocriptine fails to stop growth of eosiniphilic adenomas in acromegaly. N Engl J Med 1979; 301: 386
   Google Scholar
• Schloffer H. Frage der Operation an der Hypophyse. Bruns Beitr Klin Chir 1906; 50: 767
   Google Scholar
• Schloffer H. Erfolgreiche Operationen eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr 1907; 20: 621
   Google Scholar
• Sobinho L. G., Nunes M. C. P., Santos M. A., Mauricio J. C. Radiological evidence for regression of prolactinoma after treatment with bromocriptine. Lancet 1978; ii: 257
   Google Scholar
• Thorner M. O., Edwards C. R. W., Charlesworth M., Dacie J. E., Moult P. J. A., Rees L. H., Jones A. E., Besser G. M. Pregnancy in patients presenting with hyperprolactinaemia. A review. Br Med J 1979; ii: 771
   Google Scholar
• Tramu G., Beauvillain J. C., Mazzuca M., Grenier J. L., Fossati P., Christiaeurs J. C. Time dependent evolution of pituitary prolactin adenomas under bromocriptine therapy. Congress abstract. 2nd European Workshop of Pituitary Adenomas, ParisFrance, 1979; 87
   Google Scholar
• Tribukait B., Esposti P. L. Quantitative flowmi-crofluorometric analysis of the DNA in cells from neoplasms of the urinary bladder: correlation of aneuploidy with histological grading and the cytological findings. Urol Res 1978; 6: 201
   PubMed Web of Science ®Google Scholar
• Wass J. A. H., Moult P. J. A., Thorner M. O., Daice J. E., Charlesworth M., Jones A. E., Besser G. M. Reduction of pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 1979; ii: 66
   Google Scholar
• Wass J. A. H., Thorner Ol M., Moms D. V., Rees L. H., Mason A. S., Jones A. E., Besser G. M. Long-term treatment of acromegaly with bromocriptine. Br Med J 1977; i: 875
   Google Scholar
• Werner S., Hall K., Sjöberg H. E. Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin. Acta Endocrinol (Kbh) 1978; 88: 199
   PubMedGoogle Scholar
• Wilson C. B., Tyrell J. B. Transsphenoidal macrohypophysectomy in acromegaly. J Neurosurg 1977; 47: 840
   PubMedGoogle Scholar
• Yanai R., Nagasawa H. Effects of ergocormine and 2-Br-α-ergocriptine (CB 154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice. Experimentia (Basel) 1970; 26: 649
   PubMedGoogle Scholar